Uniphar

Uniphar EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Uniphar (UPR.IR) as of Oct 11, 2026 is 30.42. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 57.44 — a change of -47.05% (lower).

EV/FCF

30.42

YoY

-47.05%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Uniphar is 2025 30.42 . EV/FCF (Enterprise Value to Free Cash Flow) of Uniphar was 2024 57.44 . It decreases by -47.05% lower compared to the previous year.

The Uniphar EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-80.06 EUR
Jan 1, 2019
10.95 EUR
Jan 1, 2020
23.70 EUR
Jan 1, 2021
31.78 EUR
Jan 1, 2022
17.71 EUR
Jan 1, 2023
61.05 EUR
Jan 1, 2024
57.44 EUR
Jan 1, 2025
30.42 EUR
The Uniphar EV/FCF history
YEAREV/FCFYoY
30.42-47.05%
57.44-5.91%
61.05+244.70%
17.71-44.28%
31.78+34.14%
23.70+116.42%
10.95-113.68%
-80.06-51.38%
-164.69-310.52%
78.23—
Access this data via the Eulerpool API

Uniphar Stock analysis

What does Uniphar do? Uniphar PLC is an Irish company that was founded in 1994 and operates in the healthcare industry. The company is headquartered in Dublin and employs over 2,500 people worldwide. The history of Uniphar began as a pharmacy distribution company that supplied medications to retailers and healthcare facilities. Over the years, however, the company has expanded its business model and now offers a wide range of healthcare products and services. Uniphar's business model encompasses three main areas: Healthcare Services, Commercial & Clinical Supply Chain, and Product Access & Specialty Medicines. In the Healthcare Services area, Uniphar provides consulting services, training, and leadership coaching for healthcare facilities. The Commercial & Clinical Supply Chain division includes the storage, logistics, and distribution of medications, as well as the clinical care of patients. The Product Access & Specialty Medicines division focuses on access to medications with high medical demand and rare diseases. Uniphar also offers a wide range of healthcare products, including generics, branded medications, and medical devices. The company has partnerships with leading pharmaceutical companies such as Pfizer, Eli Lilly, and Merck. In recent years, Uniphar has also made several significant acquisitions to expand and diversify its business. In 2018, the company acquired UK-based pharmaceutical distributor Cahill May Roberts, and in 2019, the acquisition of Durbin, an international supplier of clinical supply products, was completed. Uniphar is committed to improving healthcare in Ireland and worldwide and offers a wide range of products and services to achieve this goal. The company has earned a reputation as a reliable partner for healthcare facilities and pharmaceutical companies and is on a steady growth trajectory. Uniphar is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Uniphar stock

EV/FCF (Enterprise Value to Free Cash Flow) of Uniphar is 30.42 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Uniphar changed from 57.44 to 30.42, representing a -47.05% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Uniphar since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Uniphar with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Uniphar

All Key Metrics — Uniphar